AllianceBernstein
RYTM icon

AllianceBernstein’s Rhythm Pharmaceuticals RYTM Stock Holding History

AllianceBernstein’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.8M Sell
894,723
-15,690
-2% -$1.42M 0.03% 475
2026
Q1 		$97.5M Sell
910,413
-19,820
-2% -$1.93M 0.03% 395
2025
Q4 		$99.6M Sell
930,233
-49,449
-5% -$5.25M 0.03% 399
2025
Q3 		$98.9M Buy
979,682
+918,212
+1,494% +$85.2M 0.03% 406
2025
Q2 		$3.88M Hold
61,470
– – ﹤0.01% 1593
2025
Q1 		$3.26M Hold
61,470
– – ﹤0.01% 1646
2024
Q4 		$3.44M Buy
61,470
+1,900
+3% +$105K ﹤0.01% 1673
2024
Q3 		$3.12M Sell
59,570
-1,500
-2% -$71.9K ﹤0.01% 1742
2024
Q2 		$2.51M Buy
61,070
+7,640
+14% +$305K ﹤0.01% 1819
2024
Q1 		$2.32M Sell
53,430
-960
-2% -$42K ﹤0.01% 1839
2023
Q4 		$2.5M Hold
54,390
– – ﹤0.01% 1817
2023
Q3 		$1.25M Hold
54,390
– – ﹤0.01% 2126
2023
Q2 		$897K Buy
+54,390
New +$982K ﹤0.01% 2338
2022
Q2 		– Sell
-44,900
Closed -$517K – 3363
2022
Q1 		$517K Buy
44,900
+100
+0.2% +$878 ﹤0.01% 2669
2021
Q4 		$447K Buy
44,800
+3,200
+8% +$35.9K ﹤0.01% 2794
2021
Q3 		$543K Hold
41,600
– – ﹤0.01% 2723
2021
Q2 		$815K Hold
41,600
– – ﹤0.01% 2619
2021
Q1 		$885K Buy
41,600
+1,500
+4% +$43.5K ﹤0.01% 2462
2020
Q4 		$1.19M Hold
40,100
– – ﹤0.01% 2222
2020
Q3 		$869K Sell
40,100
-1,200
-3% -$27.5K ﹤0.01% 2249
2020
Q2 		$921K Buy
41,300
+16,900
+69% +$329K ﹤0.01% 2248
2020
Q1 		$371K Hold
24,400
– – ﹤0.01% 2502
2019
Q4 		$560K Buy
24,400
+1,200
+5% +$26.7K ﹤0.01% 2506
2019
Q3 		$501K Buy
23,200
+4,500
+24% +$96.5K ﹤0.01% 2545
2019
Q2 		$411K Buy
18,700
+3,000
+19% +$75.8K ﹤0.01% 2701
2019
Q1 		$430K Sell
15,700
-900
-5% -$25.9K ﹤0.01% 2581
2018
Q4 		$446K Buy
16,600
+3,900
+31% +$108K ﹤0.01% 2533
2018
Q3 		$370K Buy
12,700
+5,400
+74% +$171K ﹤0.01% 2755
2018
Q2 		$228K Buy
+7,300
New +$200K ﹤0.01% 2915

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

AllianceBernstein's RYTM Position: Q2 2026 in Review

AllianceBernstein reduced its Rhythm Pharmaceuticals (RYTM) stake by 1.7% in Q2 2026, selling an estimated $1.42M and leaving 894,723 shares worth $77.8M. The position accounts for 0.03% of the portfolio, ranked #475.

AllianceBernstein first reported a position in RYTM in Q2 2018 and has held it in 29 quarters since. The position peaked at $99.6M in Q4 2025. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • AllianceBernstein held 894,723 shares of Rhythm Pharmaceuticals worth $77.8M as of Q2 2026.
  • AllianceBernstein sold 15,690 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $1.42M.
  • Rhythm Pharmaceuticals made up 0.03% of AllianceBernstein's portfolio in Q2 2026, its #475 holding.
  • AllianceBernstein first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 29 quarters since.
  • AllianceBernstein's Rhythm Pharmaceuticals position peaked at $99.6M in Q4 2025.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.